background

Research Results

2023


  • Developed Tolterodine L-tartrate
  • Developed Azilsartan medoxomil potassium
  • Developed Fenofibrate choline
  • Developed Rabeprazole sodium
  • Developed Saxagliptin
  • Developed Vonoprazan fumarate
  • Developed Sacubitril-Valsartan sodium

2022


  • Developed Alogliptin benzonate(anti-diabetic drug)
  • Developed Edoxaban tosylate hydrate(anticoagulant)
  • Developed Apixaban(anticoagulant)
  • Developed Empagliflozin(Treatment for Diabetes mellitus type 2)

2021


  • Developed Lafutidine(Treatment for gastrointestinal disorders)
  • Developed Indigo carmine(Diagnostic dye)
  • Developed Duloxetine hydrochloride(Treatment for major depressive disorder)
  • Developed Donepezil base(Treatment for Alzheimer)

2020


  • Developed Febuxostat(Treatment for hyperuricacidemia)
  • Developed Ursodeoxychlolic Acid(Hepatic enhancer)
  • Developed Fenofibric Acid(Treatment for hyperlipidemia)
  • Developed Dapagliflozin Propandiol(Treatment for Diabetes mellitus type 2)

2019


  • Developed Mirabegron(Treatment for overactive bladder)
  • Developed Aripiprazole(Treatment for schizophrenia)
  • Developed Peramivir(Antiviral drug)
  • Developed Donepezil Hydrochloride(Treatment for Alzheimer)

2018


  • Antihyperlipidemic Agent - Pitavastatin Ca (Development Completion)
  • Overactive Bladder Therapeutics - Solifenacin (Development Completion)
  • Anticoagulant - Dabigatran (Development Completion)
  • Antihyperlipidemic Agent - Fenofibrate (Development Completion)
  • Antidiabetic - Dapagliflozin (Development Completion)
  • Mucolytics Agent - Erdosteine (Development Completion)
  • Non-Steroidal anti-inflammatory druge/NSAIDs - Celecoxib (Development Completion)
  • Gastroesophageal reflux disease - Dexlansoprazole (Development Completion)

2017


  • Immunosuppressant - Azathioprine (Development Completion)
  • Antipeptic ulcer Drug - Polaprezinc (Development Completion)
  • Antiplatelet Agent - Ticagrelor (Development Completion)
  • Reflux Esophagitis - Esomeprazole Magnesium Trihydrate (Development Completion)

2016


  • Antidiabetic - Vildagliptine (Development Completion)
  • Antidiabetic - Sitagliptin Hydrochloride Hydrate (Development Completion)
  • Diabetic Neuritis Agent - R-thioctic Acid Tromethamine (Development Completion)
  • Digestive Organ Agent - Mosapride Citrate Hydrate (Development Completion)

2015


  • Antiarteriosclerotic agent - Ezetimibe (Development completion)
  • Diabetes medicine - Sitagliptin phosphate monohydrate (Development completion)
  • Hepatitis B medicine - Tenofovir disoproxil fumarate (Development completion)
  • Cerebral function improving agent - Choline alfoscerate (Development completion)
  • Digestive organ agent - Mosapride citrate hydrate (Development completion)
Address : 204 Sandan-gil Jeonui-myeon Sejong Special Self-Governing City Republic of Korea
T: 044-865-5030  ¤Ó  F: 044-865-0057  ¤Ó  M: master@koreabiochem.co.kr

COPYRIGHT 2023 ¨Ï Korea Biochem Pharm.INC.All Rights Reserved.